Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine versus nalbuphine as adjuvants to bupivacaine in paravertebral block for breast cancer surgery
PACTR201710002161189Unknown
- Sponsor
- Faculty of Medicine Fayoum University
- Start
- May 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of bupivacaine, dexmedetomidine, nalbuphine and tramadol in breast cancer (3 arms), sponsored by Faculty of Medicine Fayoum University. Primary endpoint: Analgesic consumption. Status: unknown.
02
Drugs
bupivacainedexmedetomidinenalbuphinetramadol
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR201710002161189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201710002161189.